checkAd

Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific regionLocal commercial presence to be established in Belgium, Denmark, the …

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region

Local commercial presence to be established in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics

Handeln Sie Ihre Einschätzung zu Moderna Inc!
Long
Basispreis 166,56€
Hebel 13,84
Ask 1,18
Short
Basispreis 186,47€
Hebel 12,96
Ask 1,32

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across six additional countries in Europe. Moderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally. This follows the recent announcement of plans for four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.

"Europe has played a critical role in Moderna's ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve," said Stéphane Bancel, Chief Executive Officer of Moderna. "I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe."

Europe represents an integral part of Moderna's business, with established commercial subsidiaries in Italy, France, Germany, Spain, Switzerland, and the United Kingdom. Established in 2021, Moderna Poland hosts the Moderna International Business Services (MIBS) Center, which provides critical functions, including finance, pharmacovigilance, human resources, and digital services. Moderna Poland will also expand to provide commercial capabilities.

The expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine while advancing other mRNA vaccine candidates and therapeutics. Moderna has several key manufacturing partnerships across Europe, including Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France.

Moderna's broader pipeline currently includes 40 development programs, of which 25 are in clinical trials. The Company continues to update its COVID-19 strategy to address variants of concern such as Omicron and pioneer new vaccines and therapeutics for a range of diseases and conditions. Moderna is developing mRNA medicines to potentially prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.

Seite 1 von 4
Der Analyst erwartet ein Kursziel von 169,09$, was einem Rückgang von -3,96% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
Übernehmen
Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
WerbungDisclaimer


Diskussion: Moderna
Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  215   |   |   

Schreibe Deinen Kommentar

Disclaimer

Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific regionLocal commercial presence to be established in Belgium, Denmark, the …

Nachrichten des Autors

208 Leser
168 Leser
164 Leser
164 Leser
156 Leser
708 Leser
304 Leser
264 Leser
208 Leser
192 Leser
996 Leser
832 Leser
748 Leser
708 Leser
696 Leser
4532 Leser
2851 Leser
1735 Leser
1401 Leser
1284 Leser